KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables Refunds
Ratios

BioNTech SE (BNTX) Cost of Revenue (2018 - 2025)

BioNTech SE's Cost of Revenue history spans 8 years, with the latest figure at $388.0 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 49.11% to $388.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $736.0 million, a 25.75% increase, with the full-year FY2025 number at $725.1 million, up 25.36% from a year prior.
  • Cost of Revenue hit $388.0 million in Q4 2025 for BioNTech SE, up from $173.4 million in the prior quarter.
  • Over the last five years, Cost of Revenue for BNTX hit a ceiling of $1.5 billion in Q1 2022 and a floor of $64.2 million in Q1 2024.
  • Historically, Cost of Revenue has averaged $431.3 million across 5 years, with a median of $194.6 million in 2023.
  • Biggest five-year swings in Cost of Revenue: surged 4316954698.55% in 2021 and later crashed 92.91% in 2023.
  • Tracing BNTX's Cost of Revenue over 5 years: stood at $667.2 million in 2021, then crashed by 71.94% to $187.2 million in 2022, then grew by 2.93% to $192.7 million in 2023, then soared by 35.03% to $260.2 million in 2024, then soared by 49.11% to $388.0 million in 2025.
  • Business Quant data shows Cost of Revenue for BNTX at $388.0 million in Q4 2025, $173.4 million in Q3 2025, and $86.5 million in Q2 2025.